Omodenbamab Biosimilar - Research Grade

Human

staphylococcal protein A

>1mg/ml

IgG3 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of omodenbamab, a fully human monoclonal antibody (IgG3, kappa light chain) directed against staphylococcal protein A (SpA), a surface virulence factor of Staphylococcus aureus. It is manufactured for research use only and is not the clinical drug; it is not intended for human or veterinary use. Built around the same SpA target specificity as the originator, it is useful as a defined, well-characterized binder for in-vitro and preclinical work: as a positive control or reference standard in SpA-detection and neutralization assays, for studying antibody-mediated blockade of SpA immune-evasion functions, for benchmarking anti-S. aureus antibody candidates, and for supporting assay development and format comparisons. The material is offered at research grade with low endotoxin (typically less than 1 EU/mg, with ultra-low-endotoxin lots at less than 0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support scale-up, screening campaigns, and reproducible lot-to-lot experimentation. Because it reproduces the drug's binding activity without therapeutic intent, it functions as a consistent laboratory reagent rather than a medicine. Staphylococcal protein A (SpA) is a cell-wall-anchored surface protein of Staphylococcus aureus and a major immune-evasion virulence factor. Its N-terminal region comprises several highly homologous immunoglobulin-binding domains (classically designated E, D, A, B, C) that adopt a triple-helical fold. These domains bind two host targets: the Fc (constant) region of IgG, which allows the bacterium to coat itself in antibody in a non-opsonic, "wrong-way" orientation and blunt Fc-mediated phagocytosis; and the Fab region of VH3-clan B-cell receptors, acting as a B-cell superantigen that drives apoptotic collapse of responding B cells and impairs protective antibody responses. SpA is also released and can crosslink TNFR1. Antibodies that block SpA's Ig-binding activity restore normal opsonophagocytic clearance, making SpA an attractive target for anti-staphylococcal immunotherapy research.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Omodenbamab biosimilar available in bulk or gram quantities?

A: Yes — the Omodenbamab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is research-grade Omodenbamab suitable for in vivo studies?

A: Yes, it is supplied as a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Omodenbamab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar monoclonal antibody analogous to Omodenbamab that binds staphylococcal protein A; for research use only (RUO).